Analyst Reco. Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-06-16 EDT			5-day change	1st Jan Change
54.66 ^USD	-3.03%		+0.51%	+41.61%

06-16	Protagonist Therapeutics, Inc. - Special Call
06-02	Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide	CI

Analyst Reco.

Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating	03-11	MT
Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating	03-10	MT
Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target	12-06	MT
Wedbush Initiates Protagonist Therapeutics at Outperform With $58 Price Target	11-05	MT
TD Cowen Initiates Protagonist Therapeutics at Buy	24-09-24	MT
Truist Initiates Protagonist Therapeutics at Buy With $60 Price Target	24-09-09	MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $48 From $39, Maintains Overweight Rating	24-07-25	MT
BTIG Raises Price Target on Protagonist Therapeutics to $51 From $41, Maintains Buy Rating	24-07-24	MT
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing	24-06-11	MT
Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing	24-06-11	MT
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	24-04-03	MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating	24-02-28	MT
Capital One Starts Protagonist Therapeutics With Overweight Rating, $32 Price Target	23-10-30	MT
JPMorgan Lowers Protagonist Therapeutics' Price Target to $34 From $36, Keeps Overweight Rating	23-09-25	MT
JMP Securities Raises Protagonist Therapeutics' Price Target to $35 From $28, Keeps Market Outperform Rating	23-07-06	MT
HC Wainwright Adjusts Price Target on Protagonist Therapeutics to $38 From $33, Maintains Buy Rating	23-03-16	MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $28 From $31, Maintains Market Outperform Rating	23-03-16	MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $31 From $21, Maintains Market Outperform Rating	23-03-08	MT
HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating	22-11-10	MT
JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price Target	22-08-25	MT
Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating	22-05-18	MT
SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outperform Rating	22-05-05	MT
BTIG Initiates Protagonist Therapeutics at Buy With $55 Price Target	22-02-11	MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps Market Outperform Rating	21-11-15	MT
PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics to $60 From $47, Maintains Market Outperform Rating	21-10-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Analyst Reco.

Filters